| Entry |
|
|---|
| Name |
Fluoxetine (USAN/INN);
Fluoxetine (TN) |
|---|
| Formula |
C17H18F3NO
|
|---|
| Exact mass |
309.134
|
|---|
| Mol weight |
309.3261
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01659 Selective serotonin reuptake inhibitor (SSRI)
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01644 CYP2D6 substrate
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
DG01645 CYP2D6 inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
Transporter inhibitor
DG01622 ABCB1 inhibitor
|
|---|
| Remark |
| Product (DG00942): | D00823<US> |
|
|---|
| Efficacy |
Antidepressant, Selective serotonin reuptake inhibitor (SSRI) |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2C9 [HSA: 1559], CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
CYP inhibition: CYP2C19 [HSA: 1557], CYP2D6 [HSA: 1565], CYP3A [HSA: 1576 1577 1551]
Transporter inhibition: ABCB1 [HSA: 5243]
|
|---|
| Structure map |
| map07234 | Neurotransmitter transporter inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06A ANTIDEPRESSANTS
N06AB Selective serotonin reuptake inhibitors
N06AB03 Fluoxetine
D00326 Fluoxetine (USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01659 Selective serotonin reuptake inhibitor (SSRI)
DG00942 Fluoxetine
D00326 Fluoxetine
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG00942 Fluoxetine
D00326 Fluoxetine
DG01644 CYP2D6 substrate
DG00942 Fluoxetine
D00326 Fluoxetine
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
DG00942 Fluoxetine
D00326 Fluoxetine
DG01645 CYP2D6 inhibitor
DG00942 Fluoxetine
D00326 Fluoxetine
DG02852 CYP3A/CYP3A4 inhibitor
DG00942 Fluoxetine
D00326 Fluoxetine
Transporter inhibitor
DG01622 ABCB1 inhibitor
DG00942 Fluoxetine
D00326 Fluoxetine
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC6
SLC6A4 (HTT)
D00326 Fluoxetine (USAN/INN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00326
Drug transporters
D00326
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01659 Selective serotonin reuptake inhibitor (SSRI)
DG00942 Fluoxetine
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG00942 Fluoxetine
DG01644 CYP2D6 substrate
DG00942 Fluoxetine
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
DG00942 Fluoxetine
DG01645 CYP2D6 inhibitor
DG00942 Fluoxetine
DG02852 CYP3A/CYP3A4 inhibitor
DG00942 Fluoxetine
Transporter inhibitor
DG01622 ABCB1 inhibitor
DG00942 Fluoxetine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 22
1 C1c C 19.5445 -17.2645
2 C8y C 19.5445 -18.6727
3 O2a O 20.7718 -16.5573
4 C1b C 18.3175 -16.5573
5 C8x C 18.3117 -19.3799
6 C8x C 20.7658 -19.3799
7 C8y C 21.9931 -17.2645
8 C1b C 17.1021 -17.2585
9 C8x C 18.3117 -20.7938
10 C8x C 20.7658 -20.7938
11 C8x C 21.9931 -18.6727
12 C8x C 23.2144 -16.5573
13 N1b N 15.8748 -16.5515
14 C8x C 19.5445 -21.5010
15 C8x C 23.2085 -19.3799
16 C8x C 24.4357 -17.2645
17 C1a C 14.6535 -17.2585
18 C8y C 24.4357 -18.6786
19 C1d C 25.6568 -19.3856
20 X F 26.9717 -20.0226
21 X F 26.2471 -18.3863
22 X F 24.9673 -20.5193
BOND 23
1 1 2 1
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 2
6 3 7 1
7 4 8 1
8 5 9 2
9 6 10 1
10 7 11 2
11 7 12 1
12 8 13 1
13 9 14 1
14 11 15 1
15 12 16 2
16 13 17 1
17 15 18 2
18 18 19 1
19 19 20 1
20 19 21 1
21 19 22 1
22 10 14 2
23 16 18 1
|
|---|
